BiologicalDrug
Picibanil clinical trials
Also written Picibanil and OK432.
- studies test it
- 10
- open now
- 3
- in phase 3
- 2
- first study started
- 2000
Keep track of what changes. Save the Picibanil studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2010 | 1 |
| 2015 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
Protara Therapeutics (5) · Richard JH Smith (1) · University of Iowa (1) · National Taiwan University Hospital (1) · Fukushima Medical University (1) · University of Yamanashi (1)
Often tested with
Tested in the same studies.
Lyophilized Inactivated Group A Streptococcus TARA-002 (5) · Dendritic Cell (2) · Cyclophosphamide (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses Picibanil is read from its arms, and is right about nine times in ten.
Testing it · 10
- Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerRecruitingPhase 3Protara TherapeuticsNCT07480356Written as TARA-002
- Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerRecruitingPhase 2Protara TherapeuticsNCT05951179Written as TARA-002
- Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of AgeRecruitingPhase 2Protara TherapeuticsNCT05871970Written as TARA-002
- Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)CompletedPhase 1Protara TherapeuticsNCT05085990Written as TARA-002
- Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)CompletedPhase 1Protara TherapeuticsNCT05085977Written as TARA-002
- OK432 (Picibanil) in the Treatment of Lymphatic MalformationsCompletedPhase 2Richard JH SmithNCT03427619Written as OK432
- The Efficacy of OK-432 Pleurodesis on Postoperative Air LeakStatus unknownNot applicableNational Taiwan University HospitalNCT02502643Written as OK-432 pleurodesis
- Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic MalformationsCompletedPhase 2/3University of IowaNCT00010452Written as picibanil
- Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic CancerStatus unknownPhase 1/2Fukushima Medical UniversityNCT00795977Written as dendritic cells, OK-432
- Study of Chemo-Immunotherapy in Head and Neck Cancer PatientsStatus unknownPhase 1University of YamanashiNCT01149902Written as Cyclophosphamide, Docetaxel, Dendritic cells, OK-432
Codes
What other systems call Picibanil · ClinicalTrials.gg INT008020
- MeSH (NLM) D010844PicibanilConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 2F42BH7X2LOK-432Confirmed FDA, Wikidata
- Wikidata Q1618010picibanilConfirmed FDA, Wikidata
- NCI Thesaurus C745PicibanilOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010844 | Picibanil | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 2F42BH7X2L | OK-432 | Confirmed FDA, Wikidata |
| Wikidata | Q1618010 | picibanil | Confirmed FDA, Wikidata |
| NCI Thesaurus | C745 | Picibanil | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.